In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer ...

Researchers highlight how exercise and dietary strategies may complement immunotherapy by improving immune function, tumour ...

The tumor microenvironment (TME) is a metabolically dynamic niche where cancer cells and immune cells interact to influence tumor progression and immune ...

Precise methods for shredding or repairing and replacing specific cancer-causing proteins in a malignant cell, developed at ...

Early results from the ongoing QUILT-106 clinical trial (NCT06334991) show that the treatment combination of CD19 chimeric antigen receptor natural killer (CAR-NK) cells with rituximab (Rituxan) can ...

Researchers at VCU Massey Comprehensive Cancer Center and the VCU Institute of Molecular Medicine (VIMM) were recently ...

A pair of patients with Waldenstrom’s non-Hodgkins lymphoma (NHL) remain in complete remission (CR) after 7 and 15 months ...

Stanford University-led researchers report that tumor cells hijack mitochondria from immune cells, reducing anti-tumor immune ...

Saudi Arabia leads the way as the first country to grant conditional approval for Anktiva, a groundbreaking treatment for ...

Published, peer-reviewed research shows a patent-pending, virus-mimicking platform technology developed at Purdue University ...

Early data of Waldenström’s non-Hodgkin lymphoma patients enrolled in a trial testing Immunitybio Inc.’s off-the-shelf ...

The company is restarting its solid tumor program with the Phase I trial after the company paused it to focus on blood cancer.